Atossa Therapeutics, Inc. Common Stock (ATOS) is a publicly traded Healthcare sector company. As of May 20, 2026, ATOS trades at $5.00 with a market cap of $41.16M and a P/E ratio of -1.20. ATOS moved +2.00% today. Year to date, ATOS is -47.72%; over the trailing twelve months it is -65.75%. Its 52-week range spans $3.76 to $24.90. Analyst consensus is strong buy with an average price target of $23.00. Rallies surfaces ATOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication: Atossa Therapeutics announced the acceptance of its manuscript on (Z)-endoxifen’s utrophin-modulation potential in Duchenne muscular dystrophy for publication in Degenerative Neurological and Neuromuscular Disease. The review outlines next steps including preclinical evaluation in dystrophin-deficient models and development of biomarkers measuring utrophin expression, calcium handling, and muscle composition.
| Metric | Value |
|---|---|
| Price | $5.00 |
| Market Cap | $41.16M |
| P/E Ratio | -1.20 |
| EPS | $-4.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.90 |
| 52-Week Low | $3.76 |
| Volume | 36.52K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-34.77M |
| Gross Margin | 0.00% |
3 analysts cover ATOS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.00.